Overview
Spherix’s coverage of the rheumatoid arthritis segment focuses on tracking brand usage and changes in the treatment paradigm with increasing interest in alternate mechanisms of action in the US and the EU5. We also provide detailed insights in patient characteristics that influence treatment switching decisions.
Services Available
Trending market evolution
-
Rheumatoid Arthritis (US) - quarterly, n=100
-
Rheumatoid Arthritis (EU) - semiannual, n=250
Exploring the patient journey
-
Biologic/Small Molecule Switching in RA (US) - annual, n=1,000 patient charts
-
Biologic/Small Molecule Switching in RA (EU) - annual, n=1,000 patient charts
Benchmarking new brand performance
-
Filgotinib (Gilead/Galapagos) in Rheumatoid Arthritis*
*Pending approvals and launch